Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel to evaluate FDA pharmacogenomics paper

Executive Summary

FDA will convene its Pharmaceutical Science and Clinical Pharmacology Advisory Committee March 18 to evaluate the agency's clinical pharmacogenomics concept paper. Industry is requesting that FDA clarify elements of the companion guidance, and the panel will discuss issues pertaining to collection of samples and applications of pharmacogenomics in clinical development (1"The Pink Sheet," Dec. 10, 2007, p. 18). The panel also will address qualitative clinical pharmacology. On March 19, the panel will discuss the renal impairment concept paper...

You may also be interested in...



Pharmacogenomics Draft Guidance Needs Clarification, Industry Tells FDA

Industry is pressing FDA to enhance the utility of its "companion guidance" on pharmacogenomic data submissions as the agency refines the draft document

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.

UsernamePublicRestriction

Register

PS049317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel